about
Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer.Multimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular responseEssential role of Vav family guanine nucleotide exchange factors in EphA receptor-mediated angiogenesisTOP2Ahigh is the phenotype of recurrence and metastasis whereas TOP2Aneg cells represent cancer stem cells in prostate cancer.Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacyConcomitant BET and MAPK blockade for effective treatment of ovarian cancer.Risk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics.BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.Effects of cancer-associated EPHA3 mutations on lung cancer.Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment.Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway.Eph receptors and Ephrins in cancer: common themes and controversies.A VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis.Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy.TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer.Lin28B promotes melanoma growth by mediating a microRNA regulatory circuit.A candidate gastric stem/progenitor cell marker revealed by genome-wide analysis.Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway.Overexpression of EPHA2 receptor destabilizes adherens junctions via a RhoA-dependent mechanism.Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancerInduction of Bv8 expression by granulocyte colony-stimulating factor in CD11b+Gr1+ cells: key role of Stat3 signaling.Metabolic and transcriptional profiling reveals pyruvate dehydrogenase kinase 4 as a mediator of epithelial-mesenchymal transition and drug resistance in tumor cells.Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies.An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy.Phosphoproteomic analysis implicates the mTORC2-FoxO1 axis in VEGF signaling and feedback activation of receptor tyrosine kinases.Clonality, Heterogeneity, and Evolution of Synchronous Bilateral Ovarian Cancer.Prevalence and clonality of synchronous primary carcinomas in the bladder and prostate.Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors.Preclinical Efficacy and Molecular Mechanism of Targeting CDK7-Dependent Transcriptional Addiction in Ovarian Cancer.Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase.Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancerPAX8 regulon in human ovarian cancer links lineage dependency with epigenetic vulnerability to HDAC inhibitorsRegulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via phosphatidylinositol 3-Kinase-dependent Rac1 activationComprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeuticsMolecular Targeted Therapies Elicit Concurrent Apoptotic and GSDME-Dependent Pyroptotic Tumor Cell DeathHybrid sequencing-based personal full-length transcriptomic analysis implicates proteostatic stress in metastatic ovarian cancer
P50
Q27307642-832E733F-5BD8-4763-B18D-BFC8390AA91BQ28384680-BEDE9EFD-24DA-4319-9AC1-C720E1F5A85EQ28586276-91839B4C-8146-4CF2-8BF5-4D8C38B906B0Q34619422-00DEBBE1-4928-4C90-B600-5C17F58B94FBQ35105257-75ABD24E-D2D9-4E9F-AC05-0FF97BA6AA68Q35843618-86F269E3-6488-48A4-9146-9B2EAC81F26DQ36199823-AA86CF5F-D798-4D20-9A08-845A16981CFCQ36510858-50C15D18-56BA-4819-BD6C-B102B4157461Q36727369-CC7E9C54-88FA-4215-9ADB-463C329E091DQ36762385-C3111D0B-E0AB-4D56-89CB-5BBAD3973385Q36970403-A1E468CF-9F83-427C-8D65-937A6DC11554Q37020858-0528E9BC-22AC-43F7-A967-80A2A9B7D4E7Q37157371-1EC6CC4B-EA93-408E-A560-7C9FF46382F3Q37384464-BBE79048-26E2-4DEC-B1E8-4184743A0147Q37620902-CD23E94B-A868-4529-9D95-75BF463BE088Q38864482-D87E6A18-78A9-4169-9BBC-E6E08F708790Q38970496-1B253065-7689-4413-994A-8E4016B147DFQ38971290-6B81C3D0-BFD5-41F9-A329-D43BD7D7BC4DQ39317999-65541C31-C398-4A9F-B7C8-0AEF7B9DA6A5Q40024688-4F0ECC3A-DC58-46E1-9E14-83D721A51479Q42087584-BB292166-D934-4E17-A5A2-78512151C63DQ42183046-FA0B3B1F-D7C4-4CF9-AD1B-761B312E963DQ42977115-CA270E59-8B30-42AF-8EDD-6A316301CC48Q45981705-AAC3C856-CCBD-45B1-B495-796743524FADQ46538900-D96CCCC5-E2EC-4C5D-AAB8-B5BE531E381BQ46574147-0C88BD1E-F610-4514-B826-07C64D69BC93Q47293181-F2D9780C-E0D7-4225-9616-4F8975764C13Q48202222-105EF6EB-7B56-4181-8C4E-00869372F622Q48240262-C1F6EB8F-2095-402C-87DF-8EAACF3C5A6FQ48785713-8904089A-48A2-42C0-8E3D-B8DC82486F0DQ52647644-3E4317C0-FC1C-471B-B622-9C61FAE5A18AQ58581151-2A10F67C-32AB-49E9-9F26-A30CC3FCA527Q64280891-B2C10B0A-B148-4773-BEE1-A1AA8800A5E7Q79393705-2DD34BF3-7AF7-4D56-A46F-AB20B055265BQ88044882-B7412EC2-0FFE-4297-BBB3-6AA25A953A07Q90645895-F55F807C-199C-4B31-8BAE-F6409E1D018DQ90929404-0098C933-4736-45E7-BF75-97F53FAADB4D
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Guanglei Zhuang
@ast
Guanglei Zhuang
@en
Guanglei Zhuang
@es
Guanglei Zhuang
@nl
Guanglei Zhuang
@sl
type
label
Guanglei Zhuang
@ast
Guanglei Zhuang
@en
Guanglei Zhuang
@es
Guanglei Zhuang
@nl
Guanglei Zhuang
@sl
prefLabel
Guanglei Zhuang
@ast
Guanglei Zhuang
@en
Guanglei Zhuang
@es
Guanglei Zhuang
@nl
Guanglei Zhuang
@sl
P106
P31
P496
0000-0001-8141-5096